Lidocaine and Prilocaine cream had annual sales of US $22.05 million in the United States (IQVIA MAT October 2024)
Harnessing advanced data analysis for early detection, prevention and better outcomes
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
First and only PARP inhibitor to improve overall survival in early breast cancer
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Subscribe To Our Newsletter & Stay Updated
